At Risk Of Osteoporotic Fracture — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for at risk of osteoporotic fracture. 9 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
9
Active US patents
65/100
Avg vulnerability
—
Annual revenue covered

Originators in At Risk Of Osteoporotic Fracture

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Radius 9 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating at risk of osteoporotic fracture. Each bar = one year. Y-axis scaled to peak year (3 patents).

2
27
2
31
3
38
2
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Tymlos
ABALOPARATIDE
 Radius 9 65 — 2027-10-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
RE49444 Tymlos method of use 76 2031-04-28
8748382 Tymlos method of use 75 2027-10-03
11782041 Tymlos method of use 70 2038-04-30
11255842 Tymlos method of use 70 2040-01-10
11680942 Tymlos method of use 70 2040-01-10
7803770 Tymlos method of use 68 2031-04-28
8148333 Tymlos formulation 55 2027-11-08
11977067 Tymlos formulation 55 2038-04-30
10996208 Tymlos formulation 42 2038-04-30

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10996208 Tymlos formulation 42 2038-04-30
11977067 Tymlos formulation 55 2038-04-30
8148333 Tymlos formulation 55 2027-11-08
7803770 Tymlos method of use 68 2031-04-28
11255842 Tymlos method of use 70 2040-01-10
11680942 Tymlos method of use 70 2040-01-10
11782041 Tymlos method of use 70 2038-04-30
8748382 Tymlos method of use 75 2027-10-03
RE49444 Tymlos method of use 76 2031-04-28

Related